YABAO PHARM.CORP(SH:600351)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥666,607,929.49, a decrease of 1.79% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 reached ¥45,788,516.83, an increase of 610.38% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥37,038,117.89, up 854.50% from the previous year[5]. - Basic earnings per share for Q3 2023 were ¥0.0610, reflecting a significant increase of 626.19% compared to the same period last year[6]. - The net profit attributable to shareholders for the year-to-date period reached ¥213,815,982.55, an increase of 100.11% year-on-year[5]. - Operating profit for Q3 2023 was ¥245,294,230.54, compared to ¥128,393,964.38 in Q3 2022, indicating a significant increase of 91.1%[23]. - The total profit for Q3 2023 was 244,814,694.22 CNY, compared to 127,552,149.59 CNY in Q3 2022, representing an increase of approximately 91.9%[24]. - Net profit attributable to shareholders of the parent company reached 213,815,982.55 CNY, up from 106,848,070.15 CNY in the same period last year, marking a growth of about 100.5%[24]. - Basic and diluted earnings per share for Q3 2023 were both 0.2792 CNY, compared to 0.1388 CNY in Q3 2022, reflecting an increase of approximately 100.3%[25]. - The company's total revenue for the first three quarters of 2023 reached ¥985,844,028.45, an increase of 19.5% compared to ¥824,877,196.15 in the same period of 2022[31]. - The net profit for Q3 2023 was ¥207,509,546.34, a significant increase from ¥97,633,827.47 in Q3 2022, representing a growth of 112.5%[32]. Cash Flow and Assets - The net cash flow from operating activities for Q3 2023 was ¥79,799,035.49, an increase of 75.45% year-on-year[6]. - Cash flow from operating activities for the first nine months of 2023 was 334,535,144.89 CNY, compared to 237,688,120.34 CNY in the same period of 2022, indicating a growth of about 40.7%[27]. - The net cash flow from operating activities reached ¥305.79 million, significantly up from ¥176.10 million in the first three quarters of 2022, marking a growth of 73.4%[34]. - Cash and cash equivalents decreased to CNY 583,432,604.03 from CNY 668,503,421.96, reflecting a decline of about 12.8%[17]. - Cash and cash equivalents at the end of Q3 2023 were 505,015,948.08 CNY, down from 546,998,300.82 CNY at the end of Q3 2022, a decrease of about 7.7%[27]. - The ending balance of cash and cash equivalents was ¥353.87 million, down from ¥404.99 million at the end of the same period last year, a decrease of 12.6%[35]. - The net cash flow from investing activities for Q3 2023 was -127,152,084.15 CNY, compared to -66,964,159.28 CNY in Q3 2022, indicating a worsening of investment cash flow[27]. - The net cash flow from investing activities was -¥69.03 million, worsening from -¥15.24 million in the first three quarters of 2022[34]. - The total cash inflow from sales of goods and services was approximately ¥939.36 million, an increase of 31.8% from ¥712.66 million in the first three quarters of 2022[34]. - The cash paid for purchasing goods and services was ¥211.43 million, up from ¥173.20 million in the same period last year, reflecting an increase of 22.1%[34]. - The cash paid to employees increased to ¥181.65 million from ¥172.71 million, showing a rise of 5.5% year-over-year[34]. Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥3,971,769,016.00, a decrease of 3.86% from the end of the previous year[6]. - Total assets as of Q3 2023 were ¥3,971,769,016.00, compared to ¥4,131,067,057.38 in Q3 2022, indicating a decline of 3.9%[19]. - The total assets as of September 30, 2023, amounted to ¥3,867,429,017.17, down from ¥3,991,835,603.42 at the end of 2022, reflecting a decrease of 3.1%[30]. - Total liabilities for Q3 2023 were ¥891,062,538.41, down from ¥1,124,425,007.43 in Q3 2022, representing a decrease of 20.7%[19]. - The total liabilities decreased to ¥698,384,935.61 from ¥891,868,182.98, a reduction of 21.7%[30]. - The company's total equity as of Q3 2023 was ¥3,080,706,477.59, an increase from ¥3,006,642,049.95 in Q3 2022, reflecting a growth of 2.5%[19]. - The total equity as of September 30, 2023, was ¥3,169,044,081.56, up from ¥3,099,967,420.44, an increase of 2.2%[31]. - The company reported a decrease in short-term borrowings to ¥230,219,583.33 from ¥400,462,244.44, a decline of 42.4%[30]. Shareholder Information - The company reported a total of 94,300,000 shares held by its largest shareholder, Shanxi Yabao Investment Group Co., Ltd., accounting for 12.25% of total shares[13]. - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 42,034,514 shares, representing 5.46% of total shares[13]. - The report indicates that there are no significant related party transactions among the top shareholders[14]. Research and Development - Research and development expenses for Q3 2023 amounted to ¥84,570,401.25, a decrease of 7.7% from ¥91,518,264.12 in Q3 2022[23]. - Research and development expenses for the first three quarters of 2023 were ¥60,545,419.43, slightly down from ¥64,005,191.33 in the same period of 2022, indicating a decrease of 7.2%[31]. Future Outlook - The company plans to continue expanding its market presence and developing new products to sustain growth[10]. - The company has not reported any significant new strategies or product developments during the quarter[15]. - There were no changes in the audit opinion type for the financial statements, which remain unaudited[16]. - The company has not disclosed any future performance guidance or market expansion plans in the current report[15].